Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults
Antimicrobial Agents and Chemotherapy · 03.06.2026 · 70 (6)
DOI: 10.1128/aac.01950-25 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.06.2026. Verfasst von Keith A Rodvold und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Illinois Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, beta-Lactamase Inhibitors, Ceftibuten, Cephalosporins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Ledaborbactam etzadroxil (LED-E) is an oral prodrug of ledaborbactam, a broad-spectrum β-lactamase inhibitor. In combination with ceftibuten (CTB), a third-generation oral cephalosporin, LED-E represents a potential oral β-lactam/β-lactamase inhibitor regimen for treating infections caused by drug-resistant Gram-negative pathogens. This phase 1, single-center, open-label study evaluated intrapulmonary concentrations of ledaborbactam (LED) and CTB in healthy adults. Participants in Group 1 received five oral doses of CTB/LED-E (600 mg/600 mg) every 12 h (q12h), and participants in Group 2 received five oral doses of CTB 600 mg q12h. Following the fifth dose, participants underwent a standardized single bronchoscopy with bronchoalveolar lavage (BAL). Twenty-eight participants in Group 1 and six participants in Group 2 were randomized and dosed. Among participants receiving CTB/LED-E, epithelial lining fluid (ELF) area under the concentration-time curve from 0 to 12 h (AUC 0–12 ) for aspirate 1 was 14,867 ng·h/mL for CTB and 14,529 ng·h/mL for LED, and for pooled aspirates 2 + 3 + 4 was 10,486 ng·h/mL and 9,809 ng·h/mL, respectively. ELF-to-unbound plasma AUC ratios were 0.341 (aspirate 1) and 0.239 (pooled aspirates 2 + 3 + 4) for CTB and 1.560 and 1.032, respectively, for LED. Participants receiving CTB alone demonstrated similar lung penetration, indicating no effect of LED on CTB exposure. Both CTB/LED-E and CTB alone were safe and well tolerated; all adverse events were mild or moderate and unrelated to study drug. These results demonstrate pulmonary penetration of CTB and LED and support further evaluation of CTB/LED-E for the treatment of lower respiratory tract bacterial infections caused by susceptible pathogens. This study is registered with ClinicalTrials.gov as NCT06665555 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Illinois Chicago, Chicago, Illinois, USA.
- Pulmonary Associates, PA, Phoenix, Arizona, USA.
- Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
- Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.
ORCID-Profile: Keith A Rodvold, Carlos Fernando de Oliveira, Kamal A Hamed, Karine Litherland, Marc Engelhardt, Paul C McGovern
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Rodvold, K. A., Gotfried, M. H., de Oliveira, C. F., Lowe, K., Hamed, K. A., Litherland, K., Engelhardt, M., & McGovern, P. C. (2026). Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults. Antimicrobial Agents and Chemotherapy, 70(6). https://doi.org/10.1128/aac.01950-25
Vancouver
Rodvold KA, Gotfried MH, de Oliveira CF, Lowe K, Hamed KA, Litherland K, et al. Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults. Antimicrobial Agents and Chemotherapy. 2026;70(6). doi:10.1128/aac.01950-25
BibTeX
@article{Rodvold2026,
author = {Rodvold, Keith A and Gotfried, Mark H and de Oliveira, Carlos Fernando and Lowe, Kathryn and Hamed, Kamal A and Litherland, Karine and Engelhardt, Marc and McGovern, Paul C},
title = {Plasma and intrapulmonary pharmacokinetics of ceftibuten and ledaborbactam in healthy male and female adults},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
volume = {70},
number = {6},
doi = {10.1128/aac.01950-25}
}
EUVIMED